Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Oh, D. Y., Janjigian, Y. Y., Al-Batran, S. E., Wainberg, Z. A., van Cutsem, E., Molena, D., . . . … Read More